Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features

PURPOSE: In this multicenter phase II trial, we evaluated atezolizumab combined with bevacizumab in patients with advanced renal cell carcinoma (RCC) with variant histology or any RCC histology with ≥ 20% sarcomatoid differentiation. PATIENTS AND METHODS: Eligible patients may have received previous...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: McGregor, Bradley A., McKay, Rana R., Braun, David A., Werner, Lillian, Gray, Kathryn, Flaifel, Abdallah, Signoretti, Sabina, Hirsch, Michelle S., Steinharter, John A., Bakouny, Ziad, Flippot, Ronan, Wei, Xiao X., Choudhury, Atish, Kilbridge, Kerry, Freeman, Gordon J., Van Allen, Eliezer M., Harshman, Lauren C., McDermott, David F., Vaishampayan, Ulka, Choueiri, Toni K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2020
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7051851/
https://ncbi.nlm.nih.gov/pubmed/31721643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01882
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller